Fimasartan increases glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension compared with amlodipine.

Ye Seul Yang Min Hyuk LimSeong Ok LeeMin-Seon KimChang Ho AhnSoo Heon Kwak Young Min Cho Sungwan KimAndrea MariKyong Soo ParkHye Seung Jung

Published in: Diabetes, obesity & metabolism (2018)

Compared with amlodipine, fimasartan increased late-phase glucose-stimulated insulin secretion in patients with type 2 diabetes and hypertension. This finding suggests that ARBs would be more beneficial in such patients compared with other classes of anti-hypertensives.

Keyphrases

blood pressure
hypertensive patients
end stage renal disease
ejection fraction
newly diagnosed
blood glucose
prognostic factors
adipose tissue
skeletal muscle
patient reported